· 1d · on MSN
Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
U.S. investment bank Goldman Sachs (GS) is forecasting $1 trillion U.S. of stock buybacks in 2025, the most in the past five years. Goldman Sachs analyst Scott Rubner says equity markets could get a boost in coming months following a corporate share
Read guidance, analysis, and updates on the myriad issues arising from the global response to the COVID-19 pandemic. Updated hourly every day, the insights published here are written by leading ...
After entering a technical recession in 2022, the U.S. economy has proven resilient even amid high interest rates.
Five years after the Covid-19 pandemic sent workers scrambling for home ... with few exceptions such as Goldman Sachs and Tesla, which quickly mandated full-time office attendance. Now, several major companies are abandoning the compromise approach.
A risk-taking culture, geographic advantages, and strong consumer spending continue to drive US economic growth way ahead of its peers.
Goldman Sachs expects a gradual recovery in end-market growth throughout the year as the Tools and the contract research organizations (CROs) enter 2025 after underperforming in 2024. Bioprocessing is anticipated to gain momentum as the year progresses,
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback